IC
AGIO icon

Inscription Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Inscription Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
5,540
-3,055
-36% -$92.7K 0.02% 695
2026
Q1 		$291K Hold
8,595
– – 0.03% 501
2025
Q4 		$234K Buy
+8,595
New +$302K 0.02% 561

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Inscription Capital's AGIO Position: Q2 2026 in Review

Inscription Capital reduced its Agios Pharmaceuticals (AGIO) stake by 36% in Q2 2026, selling an estimated $92.7K and leaving 5,540 shares worth $206K. The position accounts for 0.02% of the portfolio, ranked #695.

Inscription Capital first reported a position in AGIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $291K in Q1 2026. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Inscription Capital held 5,540 shares of Agios Pharmaceuticals worth $206K as of Q2 2026.
  • Inscription Capital sold 3,055 Agios Pharmaceuticals shares in Q2 2026, an estimated $92.7K.
  • Agios Pharmaceuticals made up 0.02% of Inscription Capital's portfolio in Q2 2026, its #695 holding.
  • Inscription Capital first reported a position in Agios Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Inscription Capital's Agios Pharmaceuticals position peaked at $291K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.